AIQ Solutions Featured as Small Business Success Story by Wisconsin Economic Development Corporation (WEDC)
January 10, 2024 – When AIQ Solutions was founded in 2015, UW medical oncologist Dr. Glenn Liu joined forces with UW medical physicist Dr. Robert Jeraj, Dona Alberti, a nurse at UW Hospital’s Carbone Cancer Center, and Guy Starbuck, a software architect, to seek a solution to determine if a treatment is really working for patients with late-stage cancers. Their goal of creating a new, faster, and more comprehensive way to analyze multiple radiological images at one time have come true and is now being used at several U.S. hospitals as well as sites in Australia. WEDC recently published their success story and shared their journey. To learn more, click here.
About Wisconsin Economic Development Corporation
The Wisconsin Economic Development Corporation (WEDC) is a public-private agency in the state of Wisconsin designed to assist business development and innovation through loans, grants, tax credits, and technical assistance programs. To learn more, click here.
Blackford and AIQ Solutions Announce Commercial Partnership to Bring Advanced Clinical Decision Support Tools for Metastatic Cancer to Healthcare Providers
November 14, 2023 – AIQ Solutions announced an exciting new partnership with Blackford Analysis. Under the partnership, AIQ Solutions’ innovative clinical decision support technology for oncologists, radiation oncologists, and nuclear medicine physicians treating patients with metastatic cancer will be integrated with Blackford’s advanced enterprise AI platform. Blackford’s platform and services provide healthcare professionals access to an extensive portfolio of medical AI solutions designed to drive clinical efficiency and improve patient outcomes.
“AIQ is excited about the opportunities this partnership with Blackford will bring to expand our reach to more clinicians and advance clinical care for these complex patients,” said Eric Horler, President and CEO of AIQ Solutions.
Read the full press release here.
About Blackford Analysis
Blackford are pioneers in the radiology AI space, with over a decade of experience working in partnership with leading hospitals and ground-breaking technology providers. To learn more, click here.
AIQ Technology Predicting Disease Response in Metastatic Melanoma Highlighted in Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 5, 2023 – AIQ’s latest collaboration in immunotherapy with The University of Western Australia, Sir Charles Gairdner Hospital, and Edith Cowan University was presented at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting in San Diego, CA. The study demonstrated that an AI-assisted analysis can help predict disease response using quantitative features from 18F-FDG PET-CT imaging of patients with metastatic melanoma undergoing immunotherapy. Click here to view poster.
About SITC Annual Meeting
SITC’s Annual Meeting brings together international leaders from academia, regulatory and government agencies, as well as industry representatives for unmatched education, scientific exchange and networking with the scientists driving the field. To learn more, click here.
Dr. Robert Jeraj Featured Speaker on SITC-NCI Webinar Series
November 4, 2023 – Dr. Robert Jeraj, AIQ Co-founder/Chief Scientific Officer and UW-Madison Professor, Medical Physics and Human Oncology, was a featured speaker on Course 5 of the Society for Immunotherapy of Cancer (SITC)-National Cancer Institute (NCI) webinar series. Dr. Jeraj discussed computational approaches to the Optimization of Dose and Schedule: Computational Science in Immuno-Oncology. He explained how quantitative imaging biomarkers can be combined with AI to provide unique intelligence on treatment response. Click here to view the webinar on demand.
Dr. Robert Jeraj Invited Speaker at the Prostate Cancer Foundation (PCF) Scientific Retreat
October 30, 2023 – AIQ Co-founder and Chief Scientific Officer, Dr. Robert Jeraj, was an invited speaker at the Prostate Cancer Foundation (PCF) 30th Annual Scientific Retreat in Carlsbad, CA. Dr. Jeraj, who is a Professor of Medical Physics and Human Oncology at the University of Wisconsin and has spent decades researching imaging biomarkers, co-presented a session titled “The Future of AI in Diagnostics Medicine”, that was moderated by Thomas Fuchs, DSC from Icahn School of Medicine at Mount Sinai.
About Prostate Cancer Foundation
The Prostate Cancer Foundation (PCF) funds promising research on the biology and treatment of prostate cancer, accelerating those discoveries into therapies and strategies designed to improve the quality of life and overall survival of patients. To learn more, click here.
AIQ Solutions Hosted Panel Discussion with ESSA Pharma and Xcovery on the Power of Advanced Imaging Technologies to Elevate Treatment Response Assessments
October 27, 2023 – Eric Horler, President and CEO of AIQ Solutions led a panel discussion with Alessandra Cesano, MD, PhD, CMO of ESSA Pharma and Giovanni Selvaggi, PhD, CMO of Xcovery, about the power of advanced imaging technologies to elevate treatment response assessments and optimize trial outcomes.
Advanced medical imaging is fueling new opportunities to improve understanding and quantification of cancer treatment response. Until now, the use of imaging (e.g. CT, PET, SPECT) in clinical trials has been limited to measuring a subset of lesions (usually 3-5) per scan and generalizing the results to the total disease. It has been demonstrated in published studies; however, that resistance in less than 10% of lesions can drive a poor overall clinical outcome. To comprehensively quantify treatment response, all lesions should be measured which is clinically infeasible without automation.
This discussion addressed the above challenges and explored recent clinical research applications using AIQ technology to automatically detect and measure lesion-wise response over multiple scans.
Learning Objectives:
- Detecting and quantifying lesions of change in patients with a variety of metastatic cancers
- Analyzing the importance of including heterogeneity in clinical studies and treatment assessments, the gaps it creates when not taken into account, and how this problem is handled now
- Discussing ways to properly utilize additional information obtainable from imaging
- Looking into the practicality of manually assessing all lesions in patients
- Addressing the need to compare lesions identified on different imaging modalities
Click here to access the panel discussion recording.
About ESSA Pharma
ESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of prostate cancer. To learn more, click here.
About Xcovery
Xcovery is an evidence-based, innovation-driven biopharmaceutical company in business to improve the lives of people around the world living with advanced stages of cancer. To learn more, click here.
AIQ CEO, Eric Horler, Invited Speaker at MedInvest MedTech, AI, and Digital Health Conference
October 4, 2023 –AIQ Solutions President and CEO, Eric Horler, was an invited speaker at the MedInvest MedTech, AI, and Digital Health Conference in Mountain View, CA. He spoke about how AIQ’s imaging technology is used as a clinical decision support tool for oncologists treating patients with late-stage cancers. The conference featured informative panel discussions, keynote talks, corporate presentations, and one-on-one meetings focused on medical devices, imaging technologies, diagnostics, AI/data analytics, and digital health.
About MedInvest Conference
The MedInvest Conference is a leading conference series in biotech and medtech. Each MedInvest Conference is focused on a specific indication (e.g., oncology, neurology, etc.) or area of healthcare (drug development, medtech). To learn more, click here.
Poster Presentation by GE Healthcare Featuring AIQ’s Technology at the European Association of Nuclear Medicine (EANM) Congress 2023
September 14, 2023 – GE Healthcare utilized TRAQinform IQ technologies to better understand their new PET tracer, CeriannaTM, which targets ER+ lesion status in patients with recurrent or metastatic breast cancer. The poster, titled: “Automated Lesion Detection for 18F-Fluoroestraiol PET/CT Images Demonstrate Lesion Heterogeneity in Patients with ER+ Metastatic Breast”, was presented at the European Association of Nuclear Medicine (EANM) Congress 2024 in Vienna, Austria.
Click here for link to poster.
About GE HealthCare
GE HealthCare provides digital infrastructure, data analytics & decision support tools which help in diagnosis, treatment, and monitoring of patients. To learn more, click here.
TRAQinform IQ Automated Technology Performance On-par with Inter-physician Variability and Significantly More Efficient: Published in Physics in Medicine & Biology
August 28, 2023 – TRAQinform IQ technology performs longitudinal matching of regions of interest (ROI) between images of patients with advanced metastatic cancers. Performance of TRAQinform IQ technology was compared with expert nuclear medicine physicians and published in Physics in Medicine and Biology.
TRAQinform IQ technology demonstrated high performance for matching ROI, on-par with the variability between physicians. Critically, automation significantly expedited the matching process – in high-burden cases, automated matching took an average of 4 minutes, while physicians took an average of 30-60 minutes. In the highest burden case, TRAQinform took 8 minutes, while readers took more than 120 minutes. Automated ROI matching with TRAQinform IQ enables comprehensive, ROI-level assessments in clinical practice with accurate, reproducible results.
To read the open-access paper, click here.
Two AIQ-Sponsored Abstracts Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2023
July 19, 2023 – Mikaela Dell’Oro, AIQ Solutions Research Collaborator and Research Scientist at University of Western Australia, received acceptance for two poster presentations at the European Society for Medical Oncology (ESMO) Congress 2023. We are proud to showcase our latest work at one of the most influential oncology platforms for clinicians, researchers, patient advocates, journalists, and healthcare industry representatives from around the world. AIQ also presented at the ESMO Congress in 2019 and two posters in 2022. ESMO Congress 2023 will take place in Madrid, Spain from 20 to 24 October 2023.
To learn more, (click here).
AIQ Solutions is Proud Recipient of Phase 2 SBIR Advance Programs
May 30, 2023 – AIQ Solutions is among ten companies receiving up to $850,000 to commercialize their innovations through the Small Business Innovation Research (SBIR) Advance Program. Supported by the Wisconsin Economic Development Corporation (WEDC), SBIR Advance matches up to $100,000 of federal grant dollars. AIQ qualified for the matching grant after being awarded their second of two years of a $2M grant from the National Institutes of Health. Additionally, AIQ will receive mentorship and training from the Wisconsin Center for Technology Commercialization.
Read the full news (here).
About the Center for Technology Commercialization
The Center for Technology Commercialization provides one-on-one assistance to early-stage emerging technology businesses throughout Wisconsin. From agriculture to biotechnology, Center consultants are experts in commercialization processes.
To learn more, (click here).
Dr. Timothy Perk Invited as Keynote Speaker at Webinar hosted by OneMedNet
May 15, 2023 – Dr. Tim Perk, VP of Research from AIQ Solutions will be joining a webinar hosted by OneMedNet focused on the use of real-world data (RWD) to optimize TRAQinform IQ technology for prostate cancer. Recent approval of prostate specific membrane antigen (PSMA) theranostic is rapidly changing the standard of care for diagnosing, staging and managing prostate cancer. Key challenges exist with theranostics such as identifying which patients would benefit from treatment, optimizing the therapeutic dose, monitoring and predicting treatment response, and preventing toxicity.
Key Learnings:
- How to define, identify and recruit the metastatic castration-resistant prostate cancer (mCRPC) patient cohort required to assess PSMA’s role in prostate cancer
- Leveraging imaging RWD to assess the mCRPC PET Scan
- Learning about a new technology, TRAQinform IQ, that will use standard-of-care imaging to support clinical decisions around the use of theranostics
- Understanding how TRAQinform IQ technology will be used for theranostics treatment optimization
Contact AIQ Solutions to be directed to this webinar recording and visit AIQ webinars for access to the entire library of webinars by AIQ Solutions.
About OneMedNet
OneMedNet provides high-quality, insight rich data to Life Science organizations for immediate use in Discovery, Development, Regulatory Approval, and Post-Market Surveillance.
To learn more, (click here).
AIQ Solutions Will Host Symposium at the 2023 Australia and New Zealand Society for Nuclear Medicine (ANZSNM) Annual Meeting
May 10, 2023 – AIQ will host an Industry Symposium Breakfast Session at the 2023 Australia and New Zealand Society for Nuclear Medicine (ANZSNM) annual scientific meeting in Adelaide, South Australia on the 26-28th May 2023. Professors Dale Bailey, Principal Physicist at Royal North Shore Hospital and Roslyn Francis, Associate Professor of Molecular Imaging at The University of Western Australia discussed “Does imaging hold the key to better outcomes in theranostics?”. AIQ CEO, Eric Horler, will join them to talk about “Novel Al-based technology for optimizing theranostics decision making.”
About ANZSNM
Since 1969, ANZSNM has been the professional society for people working across all areas of professional practice in nuclear medicine across Australia and New Zealand.
To learn more, (click here).
AIQ Solutions Will Present at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting
April 24, 2023 – AIQ’s collaboration with researchers at Rocky Mountain Cancer Center will be highlighted in an oral presentation at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting in Chicago, June 24-27.
The abstract title is Cross-radiotracer generalizability of automated lesion detection via CNN: pilot study in 64Cu- and 68Ga-DOTATATE PET/CT. AIQ Research Scientist, Ojaswita Lokre will be presenting on Tuesday June 27, 3:30pm CT.
To request a copy of the presentation, (click here).
About SNMMI
The Society of Nuclear Medicine and Molecular Imaging (SNMMI), headquartered in Reston, Va., is a nonprofit scientific and professional organization that promotes the science, technology and practical application of nuclear medicine and molecular imaging.
To learn more, (click here).
AIQ Solutions Named One of the Best Tech Startups in Madison
March 24, 2023 – AIQ Solutions was selected by The Tech Tribune as one of the best tech startups in Madison, Wisconsin. This designation is based on revenue potential, leadership team, brand/product traction, competitive landscape, and other factors.
To learn more, (click here).
About The Tech Tribune
Founded in 2017, The Tech Tribune delivers the latest technology news, in-depth technology articles, exclusive interviews with entrepreneurs, and insights on the hottest technology startups all over the world.
AIQ Solutions is Registered Supplier on Scientist.com
March 08, 2023 – AIQ Solutions joined scientist.com, the world’s largest digital marketplace for medical research supporting companies to accelerate therapy and radiotracer development. Among their suppliers, the biomarker supplier community offers a wide range of services. AIQ’s software technology complements the community by enabling research scientists to better understand treatment response heterogeneity and toxicity risk by analyzing radiological imaging scans.
Joining the scientist.com supplier community allows AIQ to provide timely proposals and streamline ordering processes for their clients. (Click here) to view AIQ’s profile and offerings available on scientist.com.
AIQ Co-Founder and Chief Technology Officer, Guy Starbuck, Interviewed by News Medical
February 14, 2023 – During the Society for Laboratory Automation and Screening (SLAS) international conference and exhibition, News Medical interviewed Guy Starbuck, AIQ Solutions Co-Founder and CTO. Guy provided his insights about how AI technology can be utilized to bring new medical devices to market. During this interview, Guy shared the current challenges of treating cancer, especially late-stage disease because each lesion can respond differently to treatment (response heterogeneity). He explained how AIQ technologies provide critical intelligence to oncologists supporting more confident treatment decisions.
Read the full interview (here).
About News Medical
News Medical is one of the world’s leading open-access medical and life science hubs. They were designed to put medical and life sciences information in reach of people that can make a difference. Healthcare professionals, researchers, and engaged consumers can access a wealth of open-access content from thought leaders across the world.
To learn more, (click here).
AIQ Technology Now Detects and Segments Lesions, Quantifies Lesion-Wise Response and Heterogeneity on CT Images
January 17, 2023 – In AIQ’s latest white paper, several studies demonstrate the ability of AIQ technology to detect and segment lesions and quantify lesion-wise change over time on diagnostic CT images with or without contrast-enhancement. This allows wider access of AIQ’s technology in the medical community to quantitatively evaluate all of a patient’s disease throughout care using standard of care diagnostic CT images.
Access the white paper (here).
Timothy Perk Ph.D. Promoted to Vice President of Research
January 02, 2023 – AIQ is pleased to announce that Timothy Perk, Ph.D. was promoted to Vice President of Research. Dr. Perk is an expert in advanced image and statistical analysis methods focused on developing novel techniques to quantitatively assess medical images. He will continue to provide strategic leadership, direct a team of research scientists, manage external research collaborations, and design and implement scalable technical solutions for AIQ’s innovative products, including development of new algorithms, making improvements to process automation, and enhancing the accuracy and performance of software components. He is a co-inventor of AIQ’s foundational technology, licensed from the University of Wisconsin. Prior to this position he served as a consultant with AIQ Solutions, advising on FDA 510(k) clearance process of their software and reviewed documents and performing quality control of image analysis.
Before his transition to industry, Dr. Perk was a Research Associate with Dr. Robert Jeraj at the University of Wisconsin. During this time, he served as Data Security officer for the Wisconsin Oncology Network for Imaging Excellence (WONIX), assisted in building the Networks for Imaging Excellence (NIX) alliance, an international alliance established for the purpose of accelerating research in quantitative imaging in medicine, and served as manager of the Image analysis core (IMAC).
To learn more about the AIQ Solutions Leadership Team, (click here).
Successful Completion of Medical Device Single Audit Program (MDSAP)
October 26, 2022 – AIQ is pleased to announce a successful completion of Medical Device Single Audit Program (MDSAP) certification and ISO-13485:2016 audits.
This certification validates our ongoing commitment to the highest quality assurance standards within the medical device industry as required by regulatory authorities across the world. MDSAP certification is a significant and necessary step on the path to international expansion. MDSAP certification is valid for 3 years.
To learn more, (click here).